All In Biotech

Drug Trial Radar · NCT06000956

A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Protocol of the Efficacy and Safety of Jitongning Tablets for Treating Spondyloarthritis (Kidney Yang Deficiency and Blood Stasis Obstruction)

Last checked: Nov 20, 2026Latest source record: Nov 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 408 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

408

Planned (sponsor's estimate)

Start

Sep 11, 2023

Primary completion

Dec 1, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is evaluating the efficacy and safety of Jitongning tablets in participant population. The main questions it aims to answer are: * Based on the proportion of participants who achieved improvement in ASAS20, evaluate whether the efficacy of Jitongning tablets is superior to placebo in active ax-SpA adult participants. * Evaluate the efficacy of Jitongning tablets in improving other key functions and symptom outcomes. * Evaluating the safety of Jitongning tablets in adult ax-SpA participants. Participants will 1. take orally Jitongning tablets or a simulated agent of Jitongning tablets. 2. Receive examinations and follow-up visits.

Conditions

  • Ankylosing Spondylitis

Interventions

  • Jitongning tabletsDrug

    The participants took orally three tablets of Jitongning tablets, twice a day, for 8 consecutive weeks.

  • a simulated agent of Jitongning tabletsDrug

    The participants took orally three tablets of a simulated agent of Jitongning tablets, twice a day, for 8 consecutive weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ASAS20Time frame: 8 weeks

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Dongfang Hospital, Beijing University of Chinese Medicine

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China · Recruiting

  • The First Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China · Recruiting

  • Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Suzhou Hospital of Traditional Chinese Medicine

    Suzhou, Jiangsu, China · Recruiting

  • Affiliated Hospital of North Sichuan Medical College

    Nanchong, Sichuan, China · Recruiting

  • The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

    Tianjin, Tianjin Municipality, China · Recruiting

  • Yunnan Province Hospital of Traditional Chinese Medicine

    Kunming, Yunnan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.